1. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle
2. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington
3. Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)
4. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
5. Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill
6. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
7. Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
8. Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Toronto, Ontario, Canada
9. Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
10. Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland
11. Miami Clinical Research and Baptist Health South Florida, Miami
12. Quantum Clinical Trials, Miami Beach, Florida
13. Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California
14. Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina School of Medicine, Chapel Hill
15. UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha
16. Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, Massachusetts
17. Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle
18. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego
19. for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team